Clinical Evaluation of T-2588 in Acute Lacunar Tonsillitis

DOI

Bibliographic Information

Other Title
  • 急性陰窩性扁桃炎に対するT-2588の臨床評価
  • -A Comparative Double Blind Study with Cefaclor-
  • -二重盲検法によるCefaclorとの比較試験-

Abstract

In order to compare the clinical efficacy, safety and utility of T-2588 with Cefaclor (CCL) in acute lacunar tonsillitis, a double blind trial was carried out with a daily dosage of 100mg×3 of T-2588 or 250mg×3 of CCL. The number of cases evaluated for clinical efficacy were 169 (80 treated with T-2588 and 89 treated with CCL). The effectiveness rating of T-2588 and CCL were 93.8% and 87.6% respectively, as judged by a committee; and 91.3% and 91.0% as judged by the attending physician. Bacteriological effects were satisfactory, yielding eradication rates of 97.0% with T-2588 and 97.4% with CCL. The number of cases evaluated for safety were 181 (88 treated with T-2588 and 93 treated with CCL). The incidence of side effect was 5.7% (5/88) with T-2588 and 1.1% (1/93) with CCL. The most common side effect was mild gastro-intestinal disorders. The number of cases evaluated for utility were 169 (80 treated with T-2588 and 89 treated with CCL). The usefulness rates were 93.7% with T-2588 and 92.1% with CCL. There was no significant difference between T-2588 and CCL in clinical effect, bacteriological effect, safety and utility. From these results, a daily 300mg dosage of T-2588 was as useful as a daily 750mg dosage of CCL in the treatment of acute lacunar tonsillitis.

Journal

Keywords

Details 詳細情報について

  • CRID
    1390001205500125312
  • NII Article ID
    130004133007
  • DOI
    10.11334/jibi1954.32.6_1045
  • ISSN
    04477227
  • Text Lang
    ja
  • Data Source
    • JaLC
    • CiNii Articles
  • Abstract License Flag
    Disallowed

Report a problem

Back to top